嵌合抗原受体
细胞毒性T细胞
免疫疗法
免疫系统
白细胞介素12
白细胞介素21
癌症免疫疗法
肿瘤微环境
NK-92
CD8型
抗原
癌症
生物
癌症研究
免疫学
癌细胞
体外
生物化学
遗传学
作者
Guozhu Xie,Dong Han,Yong Liang,James Dongjoo Ham,Rizwan Romee,Jianzhu Chen
出处
期刊:EBioMedicine
[Elsevier]
日期:2020-09-01
卷期号:59: 102975-102975
被引量:412
标识
DOI:10.1016/j.ebiom.2020.102975
摘要
Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. Compared to CAR-T cells, CAR-NK cells could offer some significant advantages, including: (1) better safety, such as a lack or minimal cytokine release syndrome and neurotoxicity in autologous setting and graft-versus-host disease in allogenic setting, (2) multiple mechanisms for activating cytotoxic activity, and (3) high feasibility for ‘off-the-shelf’ manufacturing. CAR-NK cells could be engineered to target diverse antigens, enhance proliferation and persistence in vivo, increase infiltration into solid tumours, overcome resistant tumour microenvironment, and ultimately achieve an effective anti-tumour response. In this review, we focus on recent progress in genetic engineering and clinical application of CAR-NK cells, and discuss current challenges and future promise of CAR-NK cells as a novel cellular immunotherapy in cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI